WO2005035498A1 - Utilisation d'un compose bicyclique azote comme agent de regulation alimentaire - Google Patents

Utilisation d'un compose bicyclique azote comme agent de regulation alimentaire Download PDF

Info

Publication number
WO2005035498A1
WO2005035498A1 PCT/JP2004/015112 JP2004015112W WO2005035498A1 WO 2005035498 A1 WO2005035498 A1 WO 2005035498A1 JP 2004015112 W JP2004015112 W JP 2004015112W WO 2005035498 A1 WO2005035498 A1 WO 2005035498A1
Authority
WO
WIPO (PCT)
Prior art keywords
hz
1h
example
methyl
echiru
Prior art date
Application number
PCT/JP2004/015112
Other languages
English (en)
Japanese (ja)
Inventor
Ryu Nagata
Teruhisa Tokunaga
Tsuyoshi Takasaki
Jun Nagamine
Mutsuo Taiji
Original Assignee
Dainippon Sumitomo Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003348940 priority Critical
Priority to JP2003-348940 priority
Application filed by Dainippon Sumitomo Pharma Co., Ltd. filed Critical Dainippon Sumitomo Pharma Co., Ltd.
Publication of WO2005035498A1 publication Critical patent/WO2005035498A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Abstract

L'invention concerne l'utilisation d'un composé représenté par la formule (1) suivante, un promédicament de celui-ci, ou un sel pharmaceutiquement acceptable d'un agent de régulation alimentaire servant d'agent thérapeutique, prophylactique ou améliorant de maladies diabétiques, etc. [Dans cette formule, R1, R2, R3, et R4 représentent chacun indépendamment hydrogène, alkyle éventuellement substitué, etc.; R5 représente aryle éventuellement substitué, etc.; X représente azote, etc.; et W1 représente la formule (2), dans laquelle n est égal à 1, 2, ou 3; m est égal à 0, 1, 2, ou 3; R7 et R8 représentent chacun indépendamment hydrogène, etc.; et R9 et R10 représentent chacun indépendamment alkyle éventuellement substitué, etc.]
PCT/JP2004/015112 2003-10-08 2004-10-06 Utilisation d'un compose bicyclique azote comme agent de regulation alimentaire WO2005035498A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2003348940 2003-10-08
JP2003-348940 2003-10-08

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005514645A JPWO2005035498A1 (ja) 2003-10-08 2004-10-06 含窒素二環性化合物の摂食調節剤としての用途

Publications (1)

Publication Number Publication Date
WO2005035498A1 true WO2005035498A1 (fr) 2005-04-21

Family

ID=34430988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/015112 WO2005035498A1 (fr) 2003-10-08 2004-10-06 Utilisation d'un compose bicyclique azote comme agent de regulation alimentaire

Country Status (2)

Country Link
JP (1) JPWO2005035498A1 (fr)
WO (1) WO2005035498A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110917A3 (fr) * 2005-04-11 2007-01-04 Mehran Seid Bagherzadeh Composes de spiro-oxindole et utilisations associees en tant qu'agents therapeutiques
WO2007032371A1 (fr) 2005-09-14 2007-03-22 Dainippon Sumitomo Pharma Co., Ltd. Dérivé d'oxindole en tant qu'agent de contrôle d'alimentation
WO2008046087A2 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
WO2008046065A1 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spirohétérocycliques et utilisations de ceux-ci comme agents thérapeutiques
WO2008060789A2 (fr) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Utilisation de composés de spiro-oxindole comme agents thérapeutiques
WO2008129994A1 (fr) 2007-04-18 2008-10-30 Kissei Pharmaceutical Co., Ltd. Dérivé à cycle fusionné azoté, composition pharmaceutique le comprenant, et son utilisation pour des usages médicaux
FR2920023A1 (fr) * 2007-08-16 2009-02-20 Sanofi Aventis Sa Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
FR2941946A1 (fr) * 2009-02-12 2010-08-13 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
FR2941947A1 (fr) * 2009-02-12 2010-08-13 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
US7799798B2 (en) 2005-04-11 2010-09-21 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
WO2011053821A1 (fr) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Antagonistes et agonistes inverses macrocycliques du récepteur de la ghréline et leurs méthodes d'utilisation
WO2011116671A1 (fr) 2010-03-22 2011-09-29 中国中化股份有限公司 Composés de diphénylamine substitués, procédé de préparation et utilisation associés
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US8450358B2 (en) 2009-06-29 2013-05-28 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
WO2013135147A1 (fr) 2012-03-14 2013-09-19 中国中化股份有限公司 Utilisation de composés de diphénylamine dans la préparation des médicaments anti-tumeurs
US9487535B2 (en) 2012-04-12 2016-11-08 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
JP2016204312A (ja) * 2015-04-23 2016-12-08 キヤノンファインテック株式会社 4−フルオロイサチン誘導体の製造方法
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000217A1 (fr) * 2000-06-29 2002-01-03 Neurosearch A/S Utilisation de derives d'oxindole 3-substitue comme modulateurs du canal potassique kcnq
JP2002523400A (ja) * 1998-08-20 2002-07-30 住友製薬株式会社 オキシインドール誘導体
WO2002060878A1 (fr) * 2001-01-30 2002-08-08 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzimidazolidinone
WO2002066426A2 (fr) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Derives de fluoro oxindole en tant que modulateurs de canaux potassium kcnq

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523400A (ja) * 1998-08-20 2002-07-30 住友製薬株式会社 オキシインドール誘導体
WO2002000217A1 (fr) * 2000-06-29 2002-01-03 Neurosearch A/S Utilisation de derives d'oxindole 3-substitue comme modulateurs du canal potassique kcnq
WO2002060878A1 (fr) * 2001-01-30 2002-08-08 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzimidazolidinone
WO2002066426A2 (fr) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Derives de fluoro oxindole en tant que modulateurs de canaux potassium kcnq

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799798B2 (en) 2005-04-11 2010-09-21 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
WO2006110917A3 (fr) * 2005-04-11 2007-01-04 Mehran Seid Bagherzadeh Composes de spiro-oxindole et utilisations associees en tant qu'agents therapeutiques
HRP20070505B1 (xx) * 2005-04-11 2014-12-19 Xenon Pharmaceuticals Inc. Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva
US7935721B2 (en) 2005-04-11 2011-05-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
EP2752417A1 (fr) * 2005-04-11 2014-07-09 Xenon Pharmaceuticals Inc. Composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques
US7700641B2 (en) 2005-04-11 2010-04-20 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
US8106087B2 (en) 2005-04-11 2012-01-31 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
EP2428515A1 (fr) * 2005-04-11 2012-03-14 Xenon Pharmaceuticals Inc. Composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques
WO2007032371A1 (fr) 2005-09-14 2007-03-22 Dainippon Sumitomo Pharma Co., Ltd. Dérivé d'oxindole en tant qu'agent de contrôle d'alimentation
JPWO2007032371A1 (ja) * 2005-09-14 2009-03-19 大日本住友製薬株式会社 摂食調節剤としてのオキシインドール誘導体
US7825155B2 (en) 2005-09-14 2010-11-02 Dainippon Sumitomo Pharma Co., Ltd. Oxindole derivative as feeding control agent
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008060789A3 (fr) * 2006-10-12 2008-07-24 Xenon Pharmaceuticals Inc Utilisation de composés de spiro-oxindole comme agents thérapeutiques
WO2008060789A2 (fr) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Utilisation de composés de spiro-oxindole comme agents thérapeutiques
WO2008046065A1 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spirohétérocycliques et utilisations de ceux-ci comme agents thérapeutiques
WO2008046087A3 (fr) * 2006-10-12 2008-11-27 Sultan Chowdhury Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
WO2008046087A2 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
CN101631546A (zh) * 2006-10-12 2010-01-20 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
AU2007319580B2 (en) * 2006-10-12 2012-11-29 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008129994A1 (fr) 2007-04-18 2008-10-30 Kissei Pharmaceutical Co., Ltd. Dérivé à cycle fusionné azoté, composition pharmaceutique le comprenant, et son utilisation pour des usages médicaux
CN103443076B (zh) * 2007-08-16 2016-06-22 赛诺菲-安万特 在3位双取代的吲哚-2-酮衍生物、其制备和其治疗应用
US8202871B2 (en) 2007-08-16 2012-06-19 Sanofi-Aventis Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
CN103443076A (zh) * 2007-08-16 2013-12-11 赛诺菲-安万特 在3位双取代的吲哚-2-酮衍生物、其制备和其治疗应用
WO2009056707A3 (fr) * 2007-08-16 2009-10-01 Sanofi-Aventis Dérivés de l'ind0l-2-0ne disubstitues en 3, leur preparation et leur application en thérapeutique
EA019486B1 (ru) * 2007-08-16 2014-04-30 Санофи-Авентис Производные индол-2-она, двузамещенные в положении 3, их получение и их применение в терапии
FR2920023A1 (fr) * 2007-08-16 2009-02-20 Sanofi Aventis Sa Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
AU2008320718B2 (en) * 2007-08-16 2013-09-19 Sanofi-Aventis Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
US9458178B2 (en) 2008-10-17 2016-10-04 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8916580B2 (en) 2008-10-17 2014-12-23 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8415370B2 (en) 2008-10-17 2013-04-09 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
WO2010092289A1 (fr) * 2009-02-12 2010-08-19 Sanofi-Aventis Derives de 3-benzofuranyl-indol-2-one substitues en position 3, leur preparation et leur application en therapeutique
CN102361864B (zh) * 2009-02-12 2015-11-25 赛诺菲 取代的3-苯并呋喃基-吲哚-2-酮-3-乙酰氨基哌嗪衍生物、其制备及其治疗用途
JP2012517461A (ja) * 2009-02-12 2012-08-02 サノフイ 三位で置換された3−ベンゾフラニル−インドール−2−オン誘導体、この調製およびこの治療的使用
JP2012517460A (ja) * 2009-02-12 2012-08-02 サノフイ 置換3−ベンゾフラニル−インドール−2−オン−3−アセトアミドピペラジン誘導体、この調製、およびこの治療的使用
US9889130B2 (en) 2009-02-12 2018-02-13 Sanofi Substituted 3-benzofuranyl-indol-2-one-3-acetamididopiperazine derivatives, preparation thereof, and therapeutic use thereof
CN102361865B (zh) * 2009-02-12 2015-11-25 赛诺菲 在3位取代的3-苯并呋喃基-吲哚-2-酮衍生物,其制备及其治疗用途
CN102361865A (zh) * 2009-02-12 2012-02-22 赛诺菲 在3位取代的3-苯并呋喃基-吲哚-2-酮衍生物,其制备及其治疗用途
RU2542991C2 (ru) * 2009-02-12 2015-02-27 Санофи Производные 3-бензофуранилиндол-2-она, замещенные в положении 3, их получение и их применение в терапии
RU2542980C2 (ru) * 2009-02-12 2015-02-27 Санофи Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии
TWI457335B (en) * 2009-02-12 2014-10-21 Sanofi Aventis 3-substituted 3-benzofuranyl-indol-2-one derivatives, preparation thereof and therapeutic application thereof
FR2941946A1 (fr) * 2009-02-12 2010-08-13 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
TWI461421B (en) * 2009-02-12 2014-11-21 Sanofi Aventis Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof and therapeutic application thereof
WO2010092288A1 (fr) * 2009-02-12 2010-08-19 Sanofi-Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
FR2941947A1 (fr) * 2009-02-12 2010-08-13 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
US9480677B2 (en) 2009-06-29 2016-11-01 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8450358B2 (en) 2009-06-29 2013-05-28 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8883840B2 (en) 2009-06-29 2014-11-11 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8742109B2 (en) 2009-10-14 2014-06-03 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9695185B2 (en) 2009-10-14 2017-07-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9260446B2 (en) 2009-10-14 2016-02-16 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011053821A1 (fr) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Antagonistes et agonistes inverses macrocycliques du récepteur de la ghréline et leurs méthodes d'utilisation
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2011116671A1 (fr) 2010-03-22 2011-09-29 中国中化股份有限公司 Composés de diphénylamine substitués, procédé de préparation et utilisation associés
US9376376B2 (en) 2012-03-14 2016-06-28 Sinochem Corporation Substitute diphenylamine compounds use thereof as antitumor agents
WO2013135147A1 (fr) 2012-03-14 2013-09-19 中国中化股份有限公司 Utilisation de composés de diphénylamine dans la préparation des médicaments anti-tumeurs
US9487535B2 (en) 2012-04-12 2016-11-08 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
JP2016204312A (ja) * 2015-04-23 2016-12-08 キヤノンファインテック株式会社 4−フルオロイサチン誘導体の製造方法
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide

Also Published As

Publication number Publication date
JPWO2005035498A1 (ja) 2006-12-21

Similar Documents

Publication Publication Date Title
US10280176B2 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US8431695B2 (en) Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
KR100769030B1 (ko) Cgrp 수용체 길항제
US9102662B2 (en) Substituted indazole derivatives active as kinase inhibitors
DK170302B1 (da) Substituerede imidazo[1,5-a]pyridinderivater og deres 7,8-dihydro- og 5,6,7,8-tetrahydroderivater samt 5H-5-(4-cyanophenyl)-6,7-dihydropyrrolo[1,2-c]imidazol-derivater og salte deraf, en fremgangsmåde til deres fremstilling, deres anvendelse til fremstilling af farmaceutiske præparater samt farmaceutiske præparater med indhold deraf
JP4754821B2 (ja) 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物
US6518265B1 (en) 1H-imidazopyridine derivatives
CN103842332B (zh) 环丙胺化合物
CA2647545C (fr) Utilisation de derives de benzotriazole et d'indazole amide substitue comme inhibiteurs de la poly(adp-ribose)polymerase (parp)
JP4691549B2 (ja) Iapの阻害剤
Wermuth et al. 3-Aminopyridazine derivatives with atypical antidepressant, serotonergic and dopaminergic activities
US6777406B2 (en) Substituted pyrroloquinolines and pyridoquinolines as serotinin agonists and antagonists
US20090215746A1 (en) Substituted pyrazolo[1,5-a]pyrimidines as calcium receptor modulating agents
US6403588B1 (en) Imidazopyridine derivatives
JP4647670B2 (ja) グリシントランスポーター1の阻害剤としてのヘテロシクリル置換フェニルメタノン
CA2484159C (fr) Sulfamides spirocycliques substitues par heteroaryle utilises comme inhibiteurs de la gamma-secretase
CA2660899C (fr) Derives de compose tricyclique utiles pour le traitement de troubles neoplastiques, de troubles inflammatoires et de troubles immunomodulatoires
KR101001811B1 (ko) 인돌, 아자인돌 및 관련 헤테로시클릭 4-알케닐 피페리딘아미드
AU2006281594B2 (en) Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
CN103906752B (zh) 杂芳基取代的吡唑并吡啶及其用作可溶性鸟苷酸环化酶刺激剂的用途
AU630251B2 (en) Dipyridodiazepines
FI82242C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-(piperidinyl)-1h-indazolderivat.
CN1186326C (zh) 丙-1,3-二酮衍生物
JP4377228B2 (ja) ベンゾイミダゾール誘導体、およびkdrキナーゼタンパク質阻害剤としてのその使用
AU2014272776B2 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2005514645

Country of ref document: JP

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase